FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137508065> ?p ?o ?g. }

• W2137508065 endingPage "262" @default.
• W2137508065 startingPage "256" @default.
• W2137508065 abstract "Axitinib is a potent, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. A randomised phase 2 trial of gemcitabine with or without axitinib in advanced pancreatic cancer suggested increased overall survival in axitinib-treated patients. On the basis of these results, we aimed to assess the effect of treatment with gemcitabine plus axitinib on overall survival in a phase 3 trial.In this double-blind, placebo-controlled, phase 3 study, eligible patients had metastatic or locally advanced pancreatic adenocarcinoma, no uncontrolled hypertension or venous thrombosis, and Eastern Cooperative Oncology Group performance status 0 or 1. Patients, stratified by disease extent (metastatic vs locally advanced), were randomly assigned (1:1) to receive gemcitabine 1000 mg/m(2) intravenously on days 1, 8, and 15 every 28 days plus either axitinib or placebo. Axitinib or placebo were administered orally with food at a starting dose of 5 mg twice a day, which could be dose-titrated up to 10 mg twice daily if well tolerated. A centralised randomisation procedure was used to assign patients to each treatment group, with randomised permuted blocks within strata. Patients, investigators, and the trial sponsor were masked to treatment assignments. The primary endpoint was overall survival. All efficacy analyses were done in all patients assigned to treatment groups for whom data were available; safety and treatment administration and compliance assessments were based on treatment received. This study is registered at ClinicalTrials.gov, number NCT00471146.Between July 27, 2007, and Oct 31, 2008, 632 patients were enrolled and assigned to treatment groups (316 axitinib, 316 placebo). At an interim analysis in January, 2009, the independent data monitoring committee concluded that the futility boundary had been crossed. Median overall survival was 8·5 months (95% CI 6·9-9·5) for gemcitabine plus axitinib (n=314, data missing for two patients) and 8·3 months (6·9-10·3) for gemcitabine plus placebo (n=316; hazard ratio 1·014, 95% CI 0·786-1·309; one-sided p=0·5436). The most common grade 3 or higher adverse events for gemcitabine plus axitinib and gemcitabine plus placebo were hypertension (20 [7%] and 5 [2%] events, respectively), abdominal pain (20 [7%] and 17 [6%]), fatigue (27 [9%] and 21 [7%]), and anorexia (19 [6%] and 11 [4%]).The addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer. These results add to increasing evidence that targeting of VEGF signalling is an ineffective strategy in this disease.Pfizer." @default.
• W2137508065 created "2016-06-24" @default.
• W2137508065 creator A5005933314 @default.
• W2137508065 creator A5010021470 @default.
• W2137508065 creator A5025882028 @default.
• W2137508065 creator A5026988448 @default.
• W2137508065 creator A5030078141 @default.
• W2137508065 creator A5040157636 @default.
• W2137508065 creator A5047712976 @default.
• W2137508065 creator A5047852139 @default.
• W2137508065 creator A5049532915 @default.
• W2137508065 creator A5055281656 @default.
• W2137508065 creator A5056197140 @default.
• W2137508065 creator A5057291927 @default.
• W2137508065 creator A5057990474 @default.
• W2137508065 creator A5063738443 @default.
• W2137508065 creator A5076696174 @default.
• W2137508065 creator A5090156519 @default.
• W2137508065 creator A5090645179 @default.
• W2137508065 date "2011-03-01" @default.
• W2137508065 modified "2023-10-14" @default.
• W2137508065 title "Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study" @default.
• W2137508065 cites W1931508686 @default.
• W2137508065 cites W1989836423 @default.
• W2137508065 cites W2080107111 @default.
• W2137508065 cites W2081974785 @default.
• W2137508065 cites W2106932520 @default.
• W2137508065 cites W2115898240 @default.
• W2137508065 cites W2116886408 @default.
• W2137508065 cites W2128095147 @default.
• W2137508065 cites W2131890640 @default.
• W2137508065 cites W2133707964 @default.
• W2137508065 cites W2139248078 @default.
• W2137508065 cites W2158134441 @default.
• W2137508065 cites W2158734599 @default.
• W2137508065 cites W2167571044 @default.
• W2137508065 cites W2170779902 @default.
• W2137508065 cites W4242589154 @default.
• W2137508065 cites W4293241248 @default.
• W2137508065 doi "https://doi.org/10.1016/s1470-2045(11)70004-3" @default.
• W2137508065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21306953" @default.
• W2137508065 hasPublicationYear "2011" @default.
• W2137508065 type Work @default.
• W2137508065 sameAs 2137508065 @default.
• W2137508065 citedByCount "344" @default.
• W2137508065 countsByYear W21375080652012 @default.
• W2137508065 countsByYear W21375080652013 @default.
• W2137508065 countsByYear W21375080652014 @default.
• W2137508065 countsByYear W21375080652015 @default.
• W2137508065 countsByYear W21375080652016 @default.
• W2137508065 countsByYear W21375080652017 @default.
• W2137508065 countsByYear W21375080652018 @default.
• W2137508065 countsByYear W21375080652019 @default.
• W2137508065 countsByYear W21375080652020 @default.
• W2137508065 countsByYear W21375080652021 @default.
• W2137508065 countsByYear W21375080652022 @default.
• W2137508065 countsByYear W21375080652023 @default.
• W2137508065 crossrefType "journal-article" @default.
• W2137508065 hasAuthorship W2137508065A5005933314 @default.
• W2137508065 hasAuthorship W2137508065A5010021470 @default.
• W2137508065 hasAuthorship W2137508065A5025882028 @default.
• W2137508065 hasAuthorship W2137508065A5026988448 @default.
• W2137508065 hasAuthorship W2137508065A5030078141 @default.
• W2137508065 hasAuthorship W2137508065A5040157636 @default.
• W2137508065 hasAuthorship W2137508065A5047712976 @default.
• W2137508065 hasAuthorship W2137508065A5047852139 @default.
• W2137508065 hasAuthorship W2137508065A5049532915 @default.
• W2137508065 hasAuthorship W2137508065A5055281656 @default.
• W2137508065 hasAuthorship W2137508065A5056197140 @default.
• W2137508065 hasAuthorship W2137508065A5057291927 @default.
• W2137508065 hasAuthorship W2137508065A5057990474 @default.
• W2137508065 hasAuthorship W2137508065A5063738443 @default.
• W2137508065 hasAuthorship W2137508065A5076696174 @default.
• W2137508065 hasAuthorship W2137508065A5090156519 @default.
• W2137508065 hasAuthorship W2137508065A5090645179 @default.
• W2137508065 hasConcept C121608353 @default.
• W2137508065 hasConcept C126322002 @default.
• W2137508065 hasConcept C142724271 @default.
• W2137508065 hasConcept C143998085 @default.
• W2137508065 hasConcept C203092338 @default.
• W2137508065 hasConcept C204787440 @default.
• W2137508065 hasConcept C27081682 @default.
• W2137508065 hasConcept C2776539811 @default.
• W2137508065 hasConcept C2779490328 @default.
• W2137508065 hasConcept C2780210213 @default.
• W2137508065 hasConcept C2780258809 @default.
• W2137508065 hasConcept C535046627 @default.
• W2137508065 hasConcept C71924100 @default.
• W2137508065 hasConceptScore W2137508065C121608353 @default.
• W2137508065 hasConceptScore W2137508065C126322002 @default.
• W2137508065 hasConceptScore W2137508065C142724271 @default.
• W2137508065 hasConceptScore W2137508065C143998085 @default.
• W2137508065 hasConceptScore W2137508065C203092338 @default.
• W2137508065 hasConceptScore W2137508065C204787440 @default.
• W2137508065 hasConceptScore W2137508065C27081682 @default.
• W2137508065 hasConceptScore W2137508065C2776539811 @default.
• W2137508065 hasConceptScore W2137508065C2779490328 @default.
• W2137508065 hasConceptScore W2137508065C2780210213 @default.

• next